ALK-Abello B

ALK-Abelló A/S is an allergy solutions company that develops treatments for respiratory allergy, anaphylaxis, food allergy, and new disease areas, operating across the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. Its portfolio includes allergy immunotherapy vaccines, injections, sublingual drops, and tablets for allergies such as grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts, as well as adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria, and ALK 014, a biologic for food allergies. Named tablet products include GRAZAX/GRASTEK, ACARIZAX, ODACTRA, MITICURE/SENSIMUNE, ITULAZAX/ITULATEK, RAGWITEK/RAGWIZAX, and CEDARCURE. The company also offers consumer healthcare solutions such as klarify.me, a digital patient engagement platform, allergen extracts for diagnosis through skin prick and blood tests, and emergency medicine treatments including adrenaline autoinjectors. It collaborates with Torii Pharmaceutical Co., Ltd. on GRAZAX and CEDARCURE, and with Dr. Reddy's Laboratories on Sensimune. Founded in 1923, ALK-Abelló A/S is headquartered in Horsholm, Denmark.